Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoradiotherapy +/- Gefitinib in Stage III NSCLC
NCT00062270Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- May 2003
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Tolerability and Toxicity. Started May 2003; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00062270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062270.